A week after Inovio Pharmaceuticals Inc. began testing its Zika vaccine, GLS-5700, in healthy volunteers, the National Institutes of Allergy and Infectious Diseases (NIAID) announced on Tuesday it has dosed the first patient in the phase I VRC 319 trial of its own Zika vaccine.